ACRIVON THERAPEUTICS INC. - COMMON STOCK

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

13 8 2025 13:15:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

14 5 2025 13:10:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

25 4 2025 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

07 4 2025 13:05:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

27 3 2025 14:44:36 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

19 3 2025 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

05 2 2025 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

13 11 2024 04:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

17 10 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16 10 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

11 10 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

14 9 2024 00:10:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

10 9 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

09 9 2024 04:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

13 8 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

29 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

14 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

24 4 2024 13:01:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

16 4 2024 17:01:49 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

10 4 2024 05:00:00 提供 Nasdaq GlobeNewswire